Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $21.7M | $31.6M | $43.3M | $559K |
| Revenue growth | — | 46.1% | 36.7% | -98.7% |
| Gross profit | $8.19M | $18.8M | $31.4M | $344K |
| Gross margin | 37.8% | 59.3% | 72.7% | 61.5% |
| Operating income | -$61.0M | -$64.4M | -$63.3M | -$91.1M |
| Operating margin | -281.9% | -203.5% | -146.4% | -16292.8% |
| Net income | -$50.3M | -$54.2M | -$45.3M | -$88.6M |
| Net margin | -232.4% | -171.4% | -104.7% | -15851.9% |
| EPS (diluted) | -$0.52 | -$0.49 | -$0.33 | -$0.63 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$57.0M | -$49.5M | -$67.6M | -$62.3M |
| Capital expenditures | $173K | $56.0K | $211K | $55.0K |
| Free cash flow | -$57.2M | -$49.5M | -$67.9M | -$62.3M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | — | $68.8M | $121M | $11.3M |
| Total assets | — | $119M | $203M | $131M |
| Total liabilities | — | $97.5M | $68.6M | $69.1M |
| Shareholders' equity | $27.2M | $22.0M | $134M | $62.3M |
| Retained earnings | — | -$432M | -$474M | -$563M |
| Shares (wtd avg diluted) | 96.6M | 111M | 139M | 142M |
Every figure is extracted from Silence Therapeutics plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.